3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
13
Rectal Neoplasms
5
Neoplasm Metastasis
4
Cholangiocarcinoma
4
Stomach Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pathologic Complete Response
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Adenocarcinoma of the Lower Rectum
1
Adenocarcinoma
1
Interventions
Nivolumab
3
tivozanib
1
regorafenib
1
neratinib
1
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
capivasertib
1
Valproic Acid
1
Thioctic Acid
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Gemcitabine
1
Fulvestrant
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Bortezomib
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Folfox protocol
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts